Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgA1 (AM130) (MALS verified)

Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgA1 (AM130) is a chimeric monoclonal antibody combining the constant domains of the human IgA1 molecule with mouse variable regions.

Product Specifications

Background

It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

CAS Number

9007-83-4

Host

HEK293

Origin Species

Mouse

Target

Spike RBD

Conjugation

Unconjugated

Tag

Human IgA1 | Human Kappa

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles.

Purity

0.95

Bioactivity

Immobilized SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H1) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgA1 (AM130) (Cat. No. S1N-M164) with a linear range of 4-125 ng/mL (QC tested).